Month: February 2025

Newsmakers

Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

February 5, 2025 admin Comments Off on Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

NASHVILLE, Tenn., Feb. 4, 2025 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. […]

Newsmakers

Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

February 5, 2025 admin Comments Off on Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

SRC recommended that the trial escalate to the next dose level of 22mg capsule No dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 — Pasithea […]